<DOC>
	<DOCNO>NCT02620332</DOCNO>
	<brief_summary>Type 1 diabetes autoimmune disease insulin secrete βcells pancreas destroyed patient reliant injection insulin adequately control blood glucose level remainder his/her life . The autoimmune process target proteins beta-cells term autoantigens . This Phase 1 study use novel investigational medicinal product ( IMP ) know MultiPepT1De study safety tolerability administration patient recent onset Type 1 diabetes . MultiPepT1De mixture peptide islet auto antigen . The mixture design induce restore immunological tolerance beta-cell thus control limit autoimmunity protect beta-cells</brief_summary>
	<brief_title>Multiple Islet Peptide Administration Type 1 Diabetes ( MultiPepT1De )</brief_title>
	<detailed_description>Recent onset type 1 diabetes patient randomize 4 group 6 subject group receive 6 injection either placebo , low , medium high dose IMP ; injection intradermal space 1 month apart .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Clinical diagnosis Type 1 diabetes Age 1845 year Maximum 4 year diagnosis Evidence ≥1 autoantibody βcell autoantigens Possession HLADR4 ( DRB1*0401 ) genotype Residual βcell function ( peak Cpeptide &gt; 200 ) Females pregnant , breastfeed use adequate form contraception . Use βcell stimulant , immunosuppressive immunomodulatory therapy , include systemic steroid within 1 month prior randomization , monoclonal antibody therapy give indication antigenspecific</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>